Misleading NDAs Beget Closer Scrutiny From FDA Staff – OND Chief Jenkins
This article was originally published in The Tan Sheet
Executive Summary
Successful appeals of NDA rejections are rare, Office of New Drugs Director John Jenkins acknowledges, but he advises pharmaceutical firms that submitting misleading applications only increases the odds against success
You may also be interested in...
Von Eschenbach Receiving HELP From Committee Members On GOP Hurdle
Senate Health, Education, Labor & Pensions Committee members are working to avert Republican holds on the nomination of FDA Acting Commissioner Andrew von Eschenbach to the permanent post
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.